Compounding Pharmacy Laws for Semaglutide Refills

8 min read

Share

A cream felt question mark.

TL;DR

Compounding pharmacy laws do not create a simple list of states where compounded semaglutide is banned. Federal requirements, state pharmacy rules, prescriber licensing, shipping permits, and company policies govern different parts of a prescription. Before treating an unavailable-state notice as a legal ban, we recommend asking for the specific rule, source, and effective date.

Compounding Pharmacy Laws: What Controls a Semaglutide Prescription

Compounding Pharmacy Laws: What Controls a Semaglutide Prescription

A denied refill does not prove that a state has banned compounded semaglutide. The cause could be a federal compounding requirement, state licensing issue, pharmacy permit, supply problem, or company policy.

Compounded drugs are not FDA-approved. The FDA does not review each compounded preparation for safety, effectiveness, and quality before it reaches a patient.

Last checked: November 3, 2026
Legal-review note: We provide general information, not legal or medical advice. Patients and clinicians should confirm current requirements with the FDA and relevant state regulators. See the change log.

Law and availability are not the same

A platform may stop serving a state because it lacks an authorized prescriber, pharmacy partner, required permit, payment coverage, or compliance process. That is not necessarily a legal ban.

We do not classify a state as banning compounded semaglutide based only on a checkout message, service map, or shipping notice.

The five checks behind each prescription

We recommend confirming:

  1. The patient’s location during the clinical visit
  2. The prescriber’s authority in that state
  3. Whether the pharmacy operates under Section 503A or 503B
  4. The pharmacy’s authority to serve the destination state
  5. The federal basis for compounding the preparation

Passing one check does not satisfy the others. A pharmacy licensed in its home state may still lack the required destination-state authority.

Change log: November 3, 2026 — clarified state-status labels, federal shortage checks, and cross-state shipping requirements.

States That Ban Compounded Semaglutide: A Source-Linked State Table

There is no reliable, permanent list of states that ban compounded semaglutide. Online lists often combine state law, pharmacy shipping limits, and platform policies.

We would not publish a definitive state table without verifying every entry against current primary sources. If no semaglutide-specific restriction is found, the careful label is “No verified semaglutide-specific restriction found as of the review date,” not “legal.”

A reliable table should include:

Required fieldWhat it should show
StatusA precise legal or operational label
Rule typeStatute, rule, order, guidance, permit limit, or policy
RegulatorThe responsible state agency
Primary sourceThe official document or database
Effective dateWhen the requirement took effect
Last reviewedWhen the source was checked
Patient effectHow prescribing, filling, or shipping is affected

How to read the state status labels

We use narrow terms:

  • Express restriction: A current legal source directly restricts the conduct.
  • State guidance: An agency has published its interpretation.
  • General rule: A broader compounding rule applies without naming semaglutide.
  • Permit limit: The pharmacy lacks authority to serve the state.
  • Platform unavailable: A company does not offer service there.
  • Verification pending: Current primary sources have not been confirmed.

We reserve ban for cases in which a current legal source supports that conclusion.

Publication standard for every state row

Each row should cite an official statute, rule, order, notice, or licensing database. It should also distinguish the publication date from the effective date and note later agency or court action.

Why the table needs continuous review

State requirements and federal policies can change. We recommend reviewing the applicable sources after FDA shortage updates, new guidance, court orders, pharmacy-board notices, or permit changes.

503A and 503B Rules in Plain Terms

503A and 503B Rules in Plain Terms

Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act establish different compounding models. Neither designation makes a compounded drug FDA-approved.

The FDA maintains a registered outsourcing facilities list. Registration confirms that a facility is listed; it is not approval of every product the facility compounds.

503A patient-specific compounding

A 503A pharmacy generally compounds for an identified patient based on a valid prescription. It must follow applicable state pharmacy and licensing requirements.

Section 503A can provide exemptions from certain federal requirements when its conditions are met. Federal law also restricts routine compounding of products that are essentially copies of commercially available drugs.

503B outsourcing facilities

A 503B outsourcing facility may compound larger batches, including certain products for healthcare-facility use. These facilities register with the FDA and are subject to current good manufacturing practice requirements and federal oversight.

They may still need state authority to distribute or dispense at the destination.

Is a 503A or 503B pharmacy better?

Neither label provides a universal quality ranking. We recommend checking the facility’s identity, state authority, ingredient information, testing claims, label instructions, beyond-use date, and adverse-event contact.

How FDA Shortage Status Changes Semaglutide Compounding

Shortage status matters because federal law restricts compounding of products that are essentially copies of commercially available drugs. Status can vary by product or presentation.

Check the live FDA Drug Shortages Database rather than assuming that one semaglutide brand’s status answers every compounding question.

What changes when a shortage ends

When a relevant approved product leaves shortage status, routine copying may face tighter limits. FDA policies can also include transition periods or later revisions.

That does not necessarily amount to a nationwide ban on every patient-specific compounded prescription. The pharmacy should be able to explain the legal basis for the preparation.

The patient-specific significant-difference pathway

Under Section 503A, a prescriber may determine that a compounded product produces a significant difference for an identified patient when the statutory conditions are satisfied.

A different dose or added ingredient does not automatically establish that basis. Price alone should not be presented as a settled clinical difference.

How to verify the current federal position

We check:

  • The FDA Drug Shortages Database
  • Current FDA compounding policies and guidance
  • FDA warning letters and safety notices
  • Relevant court orders or filings

Record the date of each source. A dated policy or enforcement announcement should not be treated as permanent.

State Licenses, Nonresident Permits, and Shipping Across State Lines

A home-state pharmacy license may not authorize shipment into another state. The destination state may require a nonresident permit, sterile-compounding credential, or other approval.

What a pharmacy license proves

An official lookup can show the named entity’s credential and status on the search date. We recommend confirming the legal name, address, permit type, expiration date, and destination-state authority.

What a pharmacy license does not prove

Licensure does not make a compounded drug FDA-approved. Nor does it prove that every ingredient, prescription, preparation method, or interstate shipment complies with applicable law.

Prescriber law and pharmacy law are separate

The prescriber’s authority and the pharmacy’s authority require separate review. Telehealth and prescribing rules may add further conditions.

For example, patients seeking GLP-1 weight-loss care in Michigan still need a valid prescribing and pharmacy pathway connected to Michigan.

Semaglutide Base, Sodium, and Acetate Are Not Interchangeable Terms

“Semaglutide base,” “semaglutide sodium,” and “semaglutide acetate” identify different chemical descriptions. They should not be assumed to have the same formulation, regulatory basis, or clinical use.

What approved semaglutide products use

Check the current FDA-approved labeling for the exact active ingredient, dosage form, and presentation. Information about one product should not automatically be extended to another.

Questions to ask before paying

Ask the prescriber or pharmacy:

  • What ingredient and chemical form are prescribed?
  • What are the concentration and dosage form?
  • Who supplied the ingredient?
  • What supports the legal basis for compounding?
  • What are the beyond-use date and storage instructions?

Patients should not switch products or change doses based on an online comparison.

Safety Standards for Compounded GLP-1 Drugs

Compounded preparations can differ in concentration, ingredient source, testing, storage, and sterility controls. “Compounded semaglutide” does not describe one uniform product.

USP <795> and <797>

USP <795> covers nonsterile compounding standards, while USP <797> addresses sterile compounding, including injectable preparations. State adoption and enforcement can vary, so we check the applicable state rule before treating a USP standard as binding law.

USP <800> only where applicable

USP <800> concerns hazardous-drug handling. It should not automatically be applied to every GLP-1 preparation without checking the drug, setting, and applicable state requirements.

Patient checks for a compounded injectable

Before use, confirm the pharmacy, ingredient, concentration, dose instructions, storage conditions, beyond-use date, package condition, and contact for questions or adverse events.

What to Do When a Semaglutide Refill Is Denied

Patients should not stop, restart, or change a dose without instructions from their treating clinician. First, identify why the refill failed.

Our prescription refill support resources can help patients organize the relevant details.

Ask for the exact reason

Request a written explanation identifying whether the issue involves federal law, a state rule, pharmacy permits, prescriber licensing, inventory, payment, or company policy. If a legal source is cited, ask for its title and date.

If the patient is moving

Tell the prescriber when the move occurs and where future visits will take place. Confirm both prescriber authority and pharmacy shipping authority before the next refill is due.

Before paying cash for another appointment

Confirm that an authorized pharmacy can fill and deliver the intended prescription. A new visit does not guarantee that the previous pharmacy pathway remains available.

FAQ

Are compounding pharmacies licensed?

States license traditional compounding pharmacies and may require nonresident permits or additional credentials. Licensure does not make compounded products FDA-approved.

What rules govern pharmacy compounding?

Applicable requirements can include federal compounding law, state pharmacy law, prescription standards, professional duties, USP standards adopted by the state, and destination-state permits.

Is a 503A or 503B pharmacy safer?

Neither designation is a universal safety score. It describes a regulatory and supply model. We recommend evaluating the specific facility, preparation, licensing, ingredient information, testing, labeling, and storage requirements.

Where can patients find official 503A and 503B lists?

There is no single federal list of every 503A pharmacy because states license traditional pharmacies. Search the relevant state board database. For 503B facilities, use the FDA’s outsourcing-facility list and then verify destination-state authority.

Does an unavailable-state notice mean compounded semaglutide is banned?

Not necessarily. It may reflect licensing, permits, staffing, inventory, payment coverage, or company policy. Ask for the exact legal source before calling it a ban.

Get Help With Your Next Refill

Keep the prescription, prescriber details, pharmacy information, and state requirements together. Temi keeps medication information in one place so patients can prepare for refill questions and act before a treatment gap occurs.

Editorial Standards

This article has not been reviewed by a licensed physician. We cite peer-reviewed studies, academic research institutions, and medical associations. Our sources are listed at the end of each article.

If you notice an error or have a concern about our content, please email supportusetemi.com.

This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider for diagnosis and treatment.

Felt Temigami re-enacting famous revolutions, from crossing the Delaware to raising a pill-bottle flag.

The revolution will be emailed.

Once a week, roughly. We're taking the fight to a corrupt and broken health insurance system. Join up.

Get Temi's newsletter by email. Unsubscribe anytime. Privacy policy

Temi

Start online, and a licensed physician reviews your request

See if you qualify

A licensed physician reviews every request. Nothing on this page is a prescription.